At Argutari Pharma we are continuously identifying compounds that possess the possibility of addressing chronic debilitating neurological conditions.
These conditions and illnesses count among them; multiple sclerosis, Parkinson’s disease as well as Alzheimer’s. We are furthermore improving research throughout numerous neurodegenerative disorders, like multiple sclerosis.
We undertake research to achieve a greater comprehension of the biological elements associated with primary neurodegenerative diseases. Our aim is to discover innovative therapeutic procedures for providing relief to patients coping with these types of chronic, incapacitating diseases.
As the number of patients and care providers looking for assistance from the health system grows, Alzheimer’s signifies an increasing issue for society. Present treatments merely tackle the symptoms and accomplish nothing to stop the development of the disease or undo the damage.
Argutari Pharma is working together with some of the world’s primary Alzheimer’s experts to determine means of halting the disease in its initial phases. Our anti-tau antibody is presently being considered to treat Alzheimer’s and progressing supra-nuclear palsy, (PSP), and is at present moving forward to phase two development.
Multiple sclerosis, is a progressive chronic disorder of the nervous system which in most cases affects patients in the 20 to 40 year age group. In MS, the body's immune system attacks proteins termed myelin, which creates a defensive layer around neuro-fibers. Whenever myelin is impaired through MS, neurons find it difficult to communicate, resulting in a build-up of neuronal loss, atrophy, and with time substantial incapacity.
We are focused on achieving the needs associated with patients having MS, and we are now helping treatment solutions that encourage nerve defence and aid neuronal regeneration.
Parkinson’s disease is the second most-common neurodegenerative condition, which affects over ten million people throughout the world. Along with our available remedies for advanced Parkinson’s, we are presently studying additional pathways that could give patients a completely new approach of treatment regarding this progressive chronic disease.
We are furthermore creating an innovative delivery system to strengthen the patient and caregiver encounter whilst administering our current treatment for Parkinson’s disease.